This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Technology, Oil & Gas and Industrials sectors led shares higher. At the close in NYSE, the...
Novartis AG (NYSE:NVS) announced that the FDA has granted a Breakthrough Therapy designation to its MET inhibitor capmatinib (INC280) for the first-line treatment of patients...
Merck & Co., Inc. (NYSE:MRK) announced that the European Commission has approved the label expansion of its PD-L1 inhibitor, Keytruda, in combination with Pfizer’s...
It has been about a month since the last earnings report for Incyte (NASDAQ:INCY). Shares have lost about 4.2% in that time frame, underperforming the S&P 500. Will the recent...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Strong Sell||Strong Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||BUY|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Neutral|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Doji Star Bearish||1M||2||Jul 19|
|Bullish Engulfing||1D||2||Sep 11, 2019|
|Three Black Crows||1H||2||Sep 13, 2019 01:00PM|
|Bank of America||30.17||30.32||29.87||+0.50||+1.69%||79.66M||13/09|
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.